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The penetration of fluconazole into human polymorphonuclear leukocytes (PMNs) and tissue culture
epithelial cells (McCoy) was evaluated. At different extracellular concentrations (0.5 to 10 mg/liter), fluconazole
reached cell-associated concentrations greater than the extracellular ones in either human PMNs (intracellular
concentration to extracellular concentration ratio, 22.2) or McCoy cells (intracellular concentration to
extracellular concentration ratio, .1.3). The uptake of fluconazole by PMNs was rapid and reversible but was
not energy dependent. The intracellular penetration of fluconazole was not affected by environmental pH or
temperature. Ingestion of opsonized zymosan and opsonized Candida albicans did not significantly increase the
amount ofPMN-associated fluconazole. At therapeutic extracellular concentrations, the intracellular activity of
fluconazole against C. albicans in PMNs was significantly lower than that of amphotericin B. It was concluded
that fluconazole reaches high intracellular concentrations within PMNs but shows moderate activity against
intracellular C. albicans in vitro.
Candida spp. are one of the most prominent fungal patho-
gens that cause severe infections in immunosuppressed
patients. Polymorphonuclear leukocytes (PMNs) are an im-
portant component of the host defense mechanisms against
Candida spp. infections. The effect of antifungal agents on
PMN activity could be an important factor in the treatment
of these infections, particularly in immunosuppressed pa-
tients.
Fluconazole is a novel antifungal agent with a bistriazole
structure that is remarkably different from other azole anti-
fungal agents; for example, it has excellent penetration into
cerebrospinal fluid and various tissues (1, 8). The pharma-
cokinetic characteristics of this drug explain the successful
use of fluconazole in the treatment of both superficial and
deep-seated infections (10, 13).
At therapeutic concentrations, fluconazole does not affect
different functions of human phagocytes in vitro, as has been
observed by different investigators (4, 9). There is not much
information, however, on the ability of this antifungal agent
to penetrate and concentrate within phagocytic and non-
phagocytic cells.
The purpose of the present study was to evaluate the
intracellular penetration of fluconazole into human PMNs
and tissue culture cells. The possible mechanism involved in
the membrane transport of this antimicrobial agent was also
evaluated. Finally, the correlation between the intracellular
penetration and activity against Candida albicans within
human PMNs was also assessed.
MATERIALS AND METHODS
Isolation of PMNs. PMNs were recovered from hepa-
rinized venous blood of healthy donors and were purified by
previously described methods (7). PMN preparations were
97% pure. Final cell suspensions were adjusted to 5 x 106
PMNs/ml in Hanks' balanced salt solution. The PMNs were
95% viable by trypan blue exclusion.
Tissue culture cells. Tissue culture epithelial cells obtained
from human synovial fluid (McCoy cells; Flow Laboratories,
* Corresponding author.
Irvine, Calif.) were grown in minimal essential medium
(Flow) supplemented with 1 mM HEPES (N-2-hydroxyeth-
ylpiperazine-N'-2-ethanesulfonic acid; Flow) and containing
10% fetal calf serum (Flow) without antibiotics. For each
experiment, cells were detached from tissue culture bottles
with trypsin-EDTA (Flow) and were suspended in Hanks'
balanced salt solution at a concentration of 5 x 106 cells per
ml.
Fluconazole uptake by cells. Uptake of radiolabeled flucon-
azole was determined by means of a velocity gradient
centrifugation technique described by Klempner and Styrt
(3). [3H]fluconazole (specific activity, about 20 Ci/mmol;
Pfizer Central Research, Sandwich, United Kingdom) was
used in the study. In these experiments, PMNs or McCoy
cells were incubated in Hanks' balanced salt solution con-
taining different concentrations of fluconazole. After differ-
ent incubation periods, the cells were separated from the
extracellular solution by centrifugation through a water-
impermeable silicone-oil barrier in a microcentrifuge tube. A
10-pl aliquot of the extracellular medium and the entire cell
pellet, obtained by cutting off the portion of the microcen-
trifuge tube containing the pellet, were placed in 3 ml of
scintillation fluid (Ready Microb; Beckman Instruments) and
counted in a liquid scintillation counter (model LS 1701;
Beckman Instruments).
The intracellular water space was measured by using
tritiated water and the extracellular marker ['4C]polyethyl-
ene glycol (3H20, 1.0 mCi/g; [14C]polyethylene glycol, 1.4
mCi/g [Du Pont, NEN Research Products, Boston, Mass.]).
The PMNs were incubated with these radiolabeled com-
pounds for 20 min at 37°C, and then the cells were separated
from the extracellular fluid by velocity gradient centrifuga-
tion as described above and counted in a liquid scintillation
counter (3). The total water content of the PMN pellet was
corrected for trapped extracellular water, i.e., polyethylene
glycol space, to obtain the intracellular water space. From
the values obtained from this procedure, PMN-associated
antimicrobial agent concentrations were calculated and ex-
pressed as a ratio of the intracellular concentration to the
extracellular concentration (C/E) (3).
Characterization of fluconazole uptake. Further studies
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were performed as described previously (5) to elucidate the
mechanism of fluconazole uptake by PMNs. The effect of
cell viability was studied by using PMNs killed by exposure
to 10% formalin for 30 min. These cells were then washed
and resuspended in fresh medium. Moreover, the influences
of environmental temperature, pH, metabolic inhibitors, and
potential competitive inhibitors were evaluated. The influ-
ence of temperature was examined by comparing antibiotic
uptake at 4 and 37°C. The pH profile of fluconazole uptake in
medium preadjusted to different external pH values (5, 7.2,
and 9) by the addition of 10 N HCI or 10 N NaOH was
measured. An inhibitor of glycolysis (sodium fluoride, 1.5 x
10-3M; Sigma Chemical Co., St. Louis, Mo.), an inhibitor of
mitochondrial oxidative metabolism (sodium cyanide, 1.5 x
10-3M; Sigma), a blocker of the proton gradient (carbonyl
cyanide m-chlorophenylhydrazone, 1.5 x 10-5M; Sigma),
and an uncoupler of oxidative phosphorylation (2,4-dinitro-
phenol, 1 x 10-4M; Sigma) were used as metabolic inhibi-
tors. The PMNs in Hanks balanced salt solution with or
without metabolic inhibitors were incubated for 30 min at
37°C (5). Fluconazole (final concentration, 2 mg/liter was
then added, and the uptake was measured as described
above.
The efflux or reversibility of binding of PMN-associated
fluconazole was also studied. The PMNs were incubated for
10 min at 37°C with fluconazole, collected by centrifugation,
and rapidly suspended in fluconazole-free medium (5). PMN-
associated fluconazole was quantitated at various time inter-
vals (5, 10, and 20 min) after removal of the extracellular
fluconazole.
Organism and susceptibility to antifungal agents. C. albi-
cans YO1-09 was kindly supplied by Pfizer Central Research
(Sandwich, United Kingdom). Susceptibility studies were
determined by a dilution technique with HR medium
(Pfizer). The MICs of fluconazole (Pfizer) and amphotericin
B (Squibb) were 1.5 and 0.25 mg/liter, respectively.
Intracellular activity of fluconazole. To evaluate the intra-
cellular activity of antifungal agents, a modification of a
previously described method was used (6). Briefly, after
preopsonization of C. albicans blastospores in 10% pooled
human serum (15 min, 37°C), 0.1 ml of yeast suspension (2 x
107 CFU/ml) and 0.1 ml of phagocytes (2 x 106 PMNs/ml)
were combined in a series of polypropylene biovials (Beck-
man Instruments) and incubated in a shaker (250 rpm) for 60
min at 37°C. Subsequent to incubation, the mixtures were
washed three times with 3 ml of ice-cold phosphate-buffered
saline by using differential centrifugation to remove extra-
cellular blastospores. Cells were then resuspended in 0.2 ml
of RPMI medium. At that time (designated time zero),
essentially all yeasts were cell associated, as evaluated by
light microscopy. The different antifungal agents were added
at different concentrations (0.5, 2, and 10 mg/liter), and the
vials were reincubated in a shaker (250 rpm) at 37°C. Vials
were removed at time zero (control) and after 3 h of
incubation (control and samples with antifungal agents), and
the phagocytes were lysed in distilled water (15 min, room
temperature). Finally, the samples were diluted and placed
onto Sabouraud agar plates and the CFU was counted after
the plates were incubated at 37°C for 2 days. All samples
were processed in duplicate. The data are expressed as the
percentage of surviving C. albicans in comparison with the
levels in controls (without antifungal agent). In addition to
determining fungal survival, morphologic studies were also
routinely performed at time zero and after 3 h of incubation
to evaluate the disposition of yeasts (cell associated or
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FIG. 1. Fluconazole uptake by human PMNs (0) and McCoy
cells ([1) at different periods of time (n = 6). Extracellular flucona-
zole concentration, 2 mg/liter.
and deposited on glass slides by using a cytocentrifuge
(Cytospin 2; Shandon Southern Instruments). After staining
with Wright's stain, samples were examined by light micros-
copy.
Statistical analysis of data. Data are expressed as means ±
standard deviations. Differences among groups were com-
pared by analysis of variance, which was used to assess
statistical significance at P < 0.05.
RESULTS
Uptake of fluconazole by human PMNs and McCoy cells.
Figure 1 shows the C/E ratios of fluconazole in human PMNs
and McCoy cells at different times. Fluconazole penetrates
into PMNs rapidly, reaching intracellular concentrations
twice as great as the extracellular ones. The C/E ratios of
fluconazole in McCoy cells were lower than those observed
in PMNs, but they were still greater than 1.
The effects of different extracellular concentrations in the
uptake of fluconazole by PMNs are shown in Fig. 2. The C/E
ratio values were greater than 2 at extracellular concentra-
tions ranging from 0.5 to 10 mg/liter.
To evaluate whether the fluconazole that had been taken
up by PMNs was tightly bound to cellular components, we
studied the kinetics of efflux (Fig. 3). The reversibility of
binding of fluconazole was rapid, with 83% of the cell-
associated drug being lost by 5 min (compare values at 10
and 15 min in Fig. 3).
The effects of cell viability, environmental temperature,
pH, and different metabolic inhibitors on fluconazole uptake
by PMNs are shown in Table 1. The intracellular penetration
of fluconazole was significantly higher when formalin-killed
cells were used. None of the other conditions affected the
C/E ratio values of this drug.
Finally, we evaluated the influence of phagocytosis and
other cell membrane stimuli on the uptake of fluconazole.
We found that ingestion of opsonized C. albicans (C/E ratio,
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FIG. 2. PMN-associated fluconazole (in milligrams per liter) at
different extracellular concentrations (n = 5). Experiments were
carried out for 20 min.
2.7 + 0.7) or zymosan (C/E ratio, 2.2 0.4) and stimulation
with phorbol myristate acetate (C/E ratio, 2.4 + 0.3) did not
affect the penetration of fluconazole into human PMNs
(control C/E ratio, 2.5 + 0.5).
Intracellular activity of fluconazole. The intracellular activ-
ity of fluconazole compared with that of amphotericin B
against C. albicans was evaluated in a 3-h assay (Fig. 4).
None of the evaluated concentrations of fluconazole signif-
icantly affected the intracellular survival of C. albicans
blastospores. Amphotericin B, however, showed significant
intracellular activity at concentrations of 2 and 10 mg/liter.
As determined by light microscopy, amphotericin B com-
pletely blocked germ tube formation of C. albicans in human
PMNs. Fluconazole, however, incompletely inhibited germ
tube formation inside of these phagocytes.
DISCUSSION
The intracellular penetration and activity of fluconazole
within phagocytic cells could be an important factor in the
treatment of severe fungal infections, especially in immuno-
suppressed patients.
The results presented above indicate that fluconazole
penetrates into human PMNs rapidly. Fluconazole reaches
concentrations in PMNs that are at least twice as great as
that in the surrounding medium. The penetration of this
imidazole antifungal agent was not affected by pH, environ-
mental temperature, or different metabolic inhibitors. The
accumulation of fluconazole does not require cell viability
and is actually enhanced by exposure of cells to formalde-
hyde. The influence of phagocytosis and cell membrane
stimuli on the uptake of fluconazole was also evaluated.
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FIG. 3. Reversibility of binding of PMN-associated fluconazole
(in milligrams per liter) after removal of the extracellular drug. Data
are means of three experiments at each time point. Cells were
centrifuged and resuspended in drug-free medium after fluconazole
accumulation for 10 min.
opsonized zymosan nor the stimulation of PMNs with phor-
bol myristate acetate affected the PMN-associated flucona-
zole concentration. These data indicate that the uptake of
fluconazole by PMNs occurs by a passive mechanism prob-
ably owing to its high lipid solubility.
The fluconazole that becomes cell associated under the
conditions of the present study is still recoverable in a fully
active form. A similar phenomenon has been described for
other antimicrobial agents such as fluoroquinolones (11).
The penetration of fluconazole into cultured epithelial
cells was lower than that observed in PMNs, but it still
reached concentrations slightly greater than the extracellular
ones. The use of the model described here offers an inter-
TABLE 1. Effects of cell viability, environmental temperature,
pH, and metabolic inhibitors on intracellular penetration
of fluconazole in human PMNs (n = 6)a
Condition C/E ratio
Viable cells at 37°C ................................. 2.6 ± 0.4
Viable cells at 4°C................................. 2.8 ± 0.6
Dead cells at 37°C................................. 4.3 ± 1.1b
pH 6................................. 2.2 0.2
pH 7................................. 2.4 0.5
pH 8................................. 2.1 0.4
Sodium fluoride ................................. 3.1 +0.6
Sodium cyanide ................................. 2.8 ± 0.5
Carbonyl cyanide m-chlorophenylhidrazone.................2.1 ± 0.4
2,4-Dinitrophenol ................................. 2.2 ± 0.7
a Experiments were carried out for 20 min with extracellular fluconazole
















































FIG. 4. Effects of amphotericin B (0) and fluconazole (1) on
killing of C. albicans ingested by human PMNs. Data are expressed
as percentages of the levels in controls (without antifungal agent) (n
= 5). *, P < 0.05.
esting insight into the penetration of antifungal agents into
nonphagocytic cells and could have relevance to infections
produced by the fungi that can invade these types of cells.
The contrast between intracellular penetration and activ-
ity has been described for a few antimicrobial agents (6). At
extracellular concentrations of between 0.5 and 10 mg/liter,
fluconazole did not affect the intracellular destruction of C.
albicans blastospores by human PMNs. At these same
concentrations, fluconazole inhibited germ tube formation
inside PMNs, although it did so incompletely. Amphotericin
B at 2 and 10 mg/liter, however, significantly enhanced the
intracellular destruction of C. albicans. Moreover, ampho-
tericin B completely blocked germ tube formation of C.
albicans in PMNs. Similar results have been described with
both antifungal agents in macrophages (12).
Since it has been demonstrated that C. albicans may resist
intracellular killing by phagocytes through the formation of
germ tubes, antifungal agents that inhibit intracellular germ
tube formation could therefore facilitate the host defense
against C. albicans. For this reason, it has been suggested
that an in vitro test that incorporates the mycelial form might
provide a better indication of the therapeutic value of the
imidazole antifungal agents than a test in which the inoculum
is the blastospore form (2, 12). The efficacy of fluconazole in
vivo seems to exhibit a better correlation with its in vitro
activity against germ tube formation than it does with the
effect of this drug on the number of blastospores (2).
Moreover, the inhibition of germ tube formation by flucon-
azole could facilitate the anticandidal activity of human
phagocytes.
In summary, fluconazole penetrates rapidly into human
PMNs by a possible passive mechanism that allows flucon-
azole to reach concentrations at least double the extracellu-
lar ones. The intracellular activity of fluconazole against
intracellular C. albicans blastospores was significantly lower
than that of amphotericin B.
ACKNOWLEDGMENT
We thank P. Hidalgo for typing the manuscript.
REFERENCES
1. Humphrey, M. J., S. Jevons, and M. H. Tarbit. 1985. Pharma-
cokinetics of UK-49.858, a metabolically stable triazole antifun-
gal drug in animals and humans. Antimicrob. Agents Che-
mother. 28:648-653.
2. Johnson, E. M., M. D. Richardson, and D. W. Warnock. 1983.
Effect of imidazole antifungals on the development of germ
tubes by strains of Candida albicans. J. Antimicrob. Che-
mother. 12:303-316.
3. Klempner, M. S., and B. Styrt. 1981. Clindamycin uptake by
human neutrophils. J. Infect. Dis. 144:472-475.
4. Odds, F. C., and C. E. Webster. 1988. Effect of azole antifungals
in vitro on host parasite interactions relevant to Candida infec-
tions. J. Antimicrob. Chemother. 22:473-481.
5. Pascual, A., I. Garcia, and E. J. Perea. 1989. Fluorometric
measurement of ofloxacin uptake by human polymorphonuclear
leukocytes. Antimicrob. Agents Chemother. 33:653-656.
6. Pascual, A., D. Tsukayama, J. Kovarik, G. Gekker, and P. K.
Peterson. 1987. Uptake and activity of rifapentine in human
peritoneal macrophages and polymorphonuclear leukocytes.
Eur. J. Clin. Microbiol. 6:152-157.
7. Peterson, P. K., J. Verhoef, D. Schmeling, and P. G. Quie. 1977.
Kinetics of phagocytosis and bacterial killing by human poly-
morphonuclear leukocytes and monocytes. J. Infect. Dis. 136:
502-509.
8. Rogers, T. E., and J. N. Galgiani. 1986. Activity of fluconazole
(UK 49,858) and ketoconazole against Candida albicans in vitro
and in vivo. Antimicrob. Agents Chemother. 30:418-422.
9. Roilides, E., T. J. Walsh, M. Rubin, D. Venzon, and P. A. Pizzo.
1990. Effects of antifungal agents on the function of human
neutrophils in vitro. Antimicrob. Agents Chemother. 34:196-
201.
10. Sugar, A. M., and C. Saunders. 1988. Oral fluconazole as
suppressive therapy of disseminated cryptococcosis in patients
with acquired immunodeficiency syndrome. Am. J. Med. 85:
481-489.
11. Tulkens, P. M. 1991. Intracellular distribution and activity of
antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 10:100-106.
12. Van't Wout, J. W., I. Meynaar, I. Linde, R. Poell, H. Mattie,
and R. Van Furth. 1990. Effect of amphotericin B, fluconazole
and itraconazole on intracellular Candida albicans and germ
tube development in macrophages. J. Antimicrob. Chemother.
25:803-811.
13. Wit, S., H. de Goossens, D. Weert, and N. Clumeclk 1989.
Comparison of fluconazole and ketoconazole for oropharyngeal
candidiasis in AIDS. Lancet i:746-747.
190 PASCUAL ET AL.
 on A
ugust 1, 2017 by U
S
E
/B
C
T
A
.G
E
N
 U
N
IV
E
R
S
IT
A
R
IA
http://aac.asm
.org/
D
ow
nloaded from
 
